The company points to research which shows that half of all pets around the world are reported to be overweight1.
That, of course, places extra load on the joints.
The new diet has been formulated to help dogs lose weight whilst still getting optimal levels of nutrients.
To help with weight loss, Hill's says it has added ingredients which change overweight pets’ gene expression and activate the metabolism to burn excess body fat.
The diet also contains omega-3-rich fish oil to support joint mobility, antioxidants and vitamins to reduce inflammation and support the immune system, and glucosamine and chondroitin, the building blocks of joint cartilage.
The diet comes in four sizes, one for small and mini dogs (1.5kg), two for medium (2.5kg, 12kg), and one for large breeds (12kg).
Hillary Noyes, Hill’s Veterinary Affairs Manager, UK & Republic of Ireland, said: "Excessive weight can increase a dog’s chances of developing mobility issues which can have a hugely detrimental effect on the animal’s health and quality of life.
"Our new Science Plan Perfect Weight & Active Mobility is the perfect solution for those who want to help their best friend maintain a healthy weight and support joints at the same time. "
For more information, speak to your local Territory Manager or visit https://www.hillspet.co.uk/dog-food/sp-canine-adult-perfect-weight-and-active-mobility-medium-chicken-dry
Reference
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
Divided into four modules, the course explores vaccines and the immune system; current and emerging strains of Leptospirosis; a practical insight into infectious disease and vaccination and the importance of getting early socialisation right.
Professor Sarah Gilbert from the Jenner Institute in Oxford presents the first CPD module. She is followed by Dr Paul Burr from Biobest Laboratories, Alan Radford from the University of Liverpool and Jon Bowen of the RVC.
John Toole, Zoetis Product Manager said: "We were extremely privileged to be able to work with such an eminent group of key opinion leaders for this CPD course. We hope participants find the interview video style of this course dynamic and insightful. Users can also find an additional module on our dog vaccine Versican Plus and how it helps meet today’s infectious disease challenges as discussed by our industry experts."
To take part in this new CPD, vets simply need to register at www.vetsupportplus.co.uk where they will be able to access all the free Zoetis learning content and receive a certificate once the CPD course is completed.
MMI seeks to address mental health and wellbeing issues within the veterinary profession, while the Doctors’ Support Network provides peer support for doctors and medical students with mental health concerns.
&me was launched this time last year at the Palace of Westminster at an event sponsored by Kevan Jones MP (Labour, North Durham,) who has spoken about his own experiences with depression.
Overall eleven &me ambassadors have volunteered their own stories with mental ill-health:
A number of &me ambassadors will be taking part in an ‘&me live’ session at BSAVA Congress, from 5-8 April 2018 in Birmingham, providing a short overview of their story before taking questions from the audience. The session will take place from 8.30 to 10.10am on Saturday 7 April and will be open to all those attending Congress.
Lizzie Lockett, RCVS CEO and Mind Matters Director, said: "The feedback our &me ambassadors have received is truly heartening.
"Steve Carter, for example, had both an ex-student and colleague comment on his story thanking him for all he’s done, while a Facebook post about Rob Pettitt reached nearly 25,000 people.
"The campaign highlights how it is possible to recover from mental ill-health and flourish in your career, with the aim of encouraging those at the start of their mental ill-health experience to seek appropriate help, whether that is something profession-specific, such as Vetlife or DSN, or their GP."
Louise Freeman, Co-Chair of the DSN, added: "Many healthcare professionals face similar pressures that can lead to mental ill-health, including long hours, intense pressure, and the nature of the job which requires practitioners to constantly provide care for others, without necessarily recognising the need for self-care at the same time.
"A recurring theme that we’ve seen from these ambassadors’ stories has been that they drew on support from friends and family, and we really hope that this campaign encourages other professionals to seek help if they feel they are struggling."
The campaign is interested in hearing from not only doctors and veterinary surgeons but also nurses, veterinary nurses, dentists, pharmacists and other healthcare professionals who want to open up about their experiences of mental ill-health.
To participate in the campaign, email Dr Louise Freeman on vicechair@dsn.org.uk.
Further information about the ‘&me’ campaign can be found at www.vetmindmatters.org/&me, and a blog by Louise, 'Me and #AndMe', can be found at www.vetmindmatters.org/me-and-andme/.
The new facility will have 9 consultation rooms and 4 theatres, and is expected to open in early 2022.
It will be Animal Trust’s 10th veterinary hospital – with existing locations in Wrexham, Yorkshire and North England.
Animal Trust now employs more than 300 vets and veterinary care staff.
A further 15 jobs will be created in Rhyl when the new hospital opens.
Owen said: “Our ethos has always been that every animal deserves access to experienced and professional veterinary care as soon as they become ill.
"That’s why we offer free consultations for sick and injured animals brought to our surgeries.
"Our clients are from all walks of life and they come to us because of what we stand for and in some cases, for the prices we offer.
“As a CIC, we try and make sure that a comprehensive veterinary service is within reach of as many pet owners as possible.
"We build large veterinary hospitals that will serve the needs of the local pet-owning community and make a positive impact on their lives.
"Our new surgery will allow us to extend our services to the residents of the North Wales coastline, many of whom currently have to travel to one of our other existing surgeries.”
Funding for Animal Trust was provided by the £500 million Wales Flexible Investment Fund.
The course will be led by Dr Jon Hall, a European Specialist in Small Animal Surgery and Dr Danielle Gunn-Moore, an RCVS-recognised Specialist in Feline Medicine, supported by RVN Ms Claire Dorey-Phillips. It will take place at Improve’s new practical training facility in Sheffield in January 2019.
Improve says the programme will equip delegates with a full understanding of the causes of FLUTD and help them to advise owners with cats suffering from the condition in order to improve long-term outcomes. It will also provide a comprehensive overview of the nursing and medical options to treat feline idiopathic cystitis (FIC) and other causes of FLUTD including infection, calculi and neoplasia. The range of appropriate surgical methods to treat ureteral obstructions will also be covered, along with the post-operative nursing care, to ensure that delegates feel ready to perform a variety of bladder surgeries with confidence.
Juliet Pope MRCVS, Veterinary Operations Manager at Improve International (pictured right), said: "Treating patients with FLUTD is a team effort so we’re offering a special rate for a vet and nurse attending from the same practice though both vets and nurses can still, of course, book independently. The cutting-edge programme will be highly interactive and we aim to send delegates back to their practices with a revitalised approach to these tricky cat cases."
For further information visit www.improveinternational.com or email enquiries@improveinternational.com or call 01793 759159.
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
The Kennel Club has written to veterinary surgeries in the UK to remind them to report caesarians and operations carried out on Kennel Club registered dogs, to help monitor and improve pedigree health.
The letter reminds vets that any operations which alter the natural conformation of a Kennel Club registered dog should be reported, as owners will need to apply for permission to compete with that dog at Kennel Club licensed shows. Vets are also asked to report caesarians as the Kennel Club will not register a litter from a bitch that has had two subsequent caesarians.
The Kennel Club says that information submitted by vets will ultimately help to improve the health of pedigree dogs as it 'provides information regarding breeding lines which may pass on certain defects and helps to deter breeders from breeding from animals with hereditary problems.'
The letter informs vets that breeders sign a declaration when registering their litter with the Kennel Club, which means that the vet will never be breaching confidentiality when reporting such operations. The declaration says: "I/we confirm and agree that any veterinary surgery performing a caesarian section and/or operation on any of my/our dogs in such a way that the operation alters the natural conformation of the dog or any part thereof may submit a report to the Kennel Club."
The declaration, regarding the reporting of operations which change natural conformation, was made a condition of Kennel Club registration in 1990 and caesarians were added to the declaration in 2010.
Caroline Kisko, Kennel Club Secretary, said: "The veterinary profession and the Kennel Club both hold valuable information about pedigree dogs but by sharing this information we will get a much more accurate picture about dog health.
Although some vets report operations to the Kennel Club this is not a uniform practice, but we hope this reminder will help to ensure that we work more closely together in the future."
Vets have been sent a copy of the reporting form that they should use and the link to where the forms can be downloaded from the Kennel Club website www.thekennelclub.org.uk/item/3310. The BVA has also produced a list of frequently asked questions about veterinary reporting at www.bva.co.uk/publications_and_resources/Forms.aspx
Dechra Veterinary Products has launched Osphos, an intramuscular clodronic acid injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses, the only such licensed product in the UK.
Dechra says it expects Osphos to change the way chronic lameness caused by navicular syndrome is tackled by equine vets.
According to the company, clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days post treatment.
Dechra brand manager Emma Jennings said: "Osphos intramuscular injection contains the bisphosphonate clodronic acid which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.
"We are delighted with the results of the trials, which proved that Osphos is effective at 6 months post-treatment. We're looking forward to being able to support equine vets, vet nurses and practices by providing an intramuscular Clodronic acid injection for horses."
Dechra also says studies showed that mild transient colic was seen following just 1.6 per cent of treatments.
Osphos 60 mg/ml solution for injection for horses is available from September 2014.
Pockit Central is a benchtop analyser which completes tests in 85 minutes.
The new PCR tests include: Lyme disease, Dirofilaria immitis, Neospora caninum, Pseudomonas aeruginosa, Mec A gene for MRSA, IBR and C. difficile. The system has tests tailored to small animal, equine and farm practice, with specialist assays also available for poultry and aquaculture.
The new additions extend the capabilities of the Pockit to more than 190 assays, testing up to 8 pathogens in one run. Horiba says the Pockit is so easy to set up that a laboratory can be up and running within 30 minutes with staff training provided.
Horiba has also published its recent veterinary CPD webinar in which the value of in-house PCR analysis for pathogen screening is discussed with the Head of ESCCAP (European Scientific Council for Companion Animal Parasites) UK & Ireland, in conjunction with the importance of screening imported dogs: The webinar is available to watch on-demand at: https://www.horiba.com/en_en/veterinary/support/webinars/
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
The company's new van has a range of 146 miles before it needs recharging, and it can be recharged to 80% within 40 minutes.
That puts 60% of MWI's customers within range of its distribution centre in Stoke-on-Trent, including those in Manchester and Birmingham.
As part of its drive to establish more sustainable operations, MWI has also launched a pilot with one of its corporate customers in which they reduce the number of deliveries made per week – adopting a two or three-day a week delivery system.
The company says that since January, that has resulted in 700,000 fewer vehicle miles.
Research commissioned by Bayer Animal Health has revealed that dogs really do look like their owners.
The research, which is being used to promote Drontal Bone, the company's new bone-shaped wormer, was conducted amongst 3,000 British dog-lovers. It found that the overwhelming majority of owners share at least one common physical attribute with their pet, whilst one in ten owners could be described as the spitting image of their dog, sharing six or more physical attributes:
As part of the campaign, Bayer has launched the Give Your Dog a Bone competition, a nationwide search to find the UK's "Top Dog". The competition is split into four video and photographic categories, with one open exclusively to dogs that have formed a special bond with their owner. Top dogs can enter via the competition website - www.giveyourdogabone.co.uk - where owners can upload photos, videos, and explain in under 100 words why they think their pet should win a Drontal 'Bonies' award.
Give Your Dog a Bone Judge Emma Milne MRCVS, said: "When dogs seem to have the same characteristics as their owners, it could be because people subconsciously choose a pet that resembles themselves. It is often found that more energetic breeds, such as s Red Setter have an owner who is sporty and most happy when taking their pet on long country walks, while a glamorous owner who enjoys grooming themselves might choose a dog which also requires lots preening, such as a Maltese Terrier. The Give Your Dog a Bone awards give us the chance to recognise the unique traits and talents that make dogs such an important part of our lives. With four very different categories, this competition will be wide open to dogs of all shapes, sizes and personalities!"
Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
The hour-long webinar will be held on Tuesday 18th May from 7.30pm.
Chris is a European and RCVS Recognised Specialist in Equine Dentistry and the founding Director of the Equine Dental Clinic Ltd. Nicole is a European, American and RCVS Recognised Specialist in Equine Dentistry and is a co-director of the Equine Dental Clinic.
Chris and Nicole (pictured right) will discuss key points for examination, diagnostics and treatment, including:
Zoetis Equine Product Manager, Penny McCann said: "Chris Pearce and Nicole du Toit are known worldwide for their consulting, training, educating and CPD, as well as for running the longest established and largest equine veterinary dental specialist practice in Europe.
"We are delighted that they have agreed to share their knowledge with our client practices on 18th May and look forward to welcoming you."
To book your place for the webinar, visit: https://register.gotowebinar.com/register/173596806534344203
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 8034.
The BSAVA has launched a series of client information sheets for drugs commonly used off-label.
The information sheets were the brainchild of Professor Ian Ramsey, Editor-in-Chief of the BSAVA Small Animal Formulary. He said: "As a referral vet I write a lot of letters to owners and vets that include instructions about the drugs that I am prescribing or dispensing for a patient. Often these drugs are unusual or cytotoxic, and are very commonly only authorized for human patients. As Editor of the Formulary I am acutely aware of the responsibility that I have for making sure owners understand what these drugs are for and what the side effects might be."
The BSAVA says it hopes the leaflets will overcome the challenge veterinary surgeons have in remembering all the drug information that needs to be related to clients, and the problem of clients forgetting what they have been told verbally by the clinician during a consultation.
In addition to a basic introduction to the Prescribing Cascade, each of the client leaflets provides the following information:
The first batch of client information leaflets, which relate to the following medications prescribed for dogs and cats, is now available for members to download from the BSAVA website (http://www.bsava.com/):
Each of the leaflets has a space for veterinary practices to add their details before distributing them to their clients, and the BSAVA says more may be added during 2011.
Matt Yarnall from Boehringer Ingelheim said: "This is fantastic news for Bovela which offers a truly unique and innovative way of controlling BVD in a herd, something that is now clearly being appreciated by farmers and vets alike."
The company says over 5 million doses of Bovela have now been sold across Europe2 showing how quickly farmers have understood the benefits of a single dose vaccine that provides a full 12 months of live vaccine protection.
Matt added: "Feedback we have from vets and farmers throughout Europe shows two main things. Firstly, for those who haven’t controlled BVD before, there is the realisation of how much better herd health can be and secondly, for those who have previously struggled with multiple primary course vaccines or those that should be boosted every six months, there is relief at Bovela’s easy-to-follow regime."
References
The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
Matt has taken over as hospital director from David Walker, who has now moved to the role of referrals managing director in the south of the UK for Linnaeus.
Matt said: “I certainly have some big shoes to fill but working as clinical director alongside David was a great grounding and we work well together.
“Essentially, I was his running mate back then but now I am stepping up to take on the main role, with all the additional responsibilities it entails, and I’m determined to make it my own.
“I know I have the drive, the desire, the clarity of purpose and the dedication to succeed.
"I also know what an incredible operation I have inherited from David.
“One of the key things about Anderson Moores is that every member of the team works together in the same location to support every aspect of a pet’s treatment and recovery, so whatever service they may need is all available under the same roof.”
www.andersonmoores.com/homewww.zeropainphilosophy.com
ECM of France, a specialist in veterinary ultrasound solutions, has launched VIRTUAL SCAN - an ultrasound scanner for pig farmers and veterinarians. ECM says the scanner offers an alternative to screenless A-Mode Doppler devices, cheaper ultrasound devices, which are often poor quality.
VIRTUAL SCAN weighs 450 grams. It is equipped with an internal five-hour battery and a 5MHz sector probe. ECM says the instrument is extremely easy to handle - all the user needs to do is switch it on and the hand-held instrument is instantly ready to perform an ultrasound on sows.
VIRTUAL SCAN is a compact device (11cm x 18.5cm x 4.5cm) and does not require an external cable. According to the company, it can be used in any livestock facility, even inside narrow, hard-to-reach stalls. The screen is positioned in such a way that the image is always visible.
Using ECM's scanner, pregnancy tests can be performed as early as 21 days after insemination, so it is possible to re-inseminate any unfertilised sow without wasting a costly additional cycle. The image is easy to interpret. After use, the VIRTUAL SCAN ultrasound instrument is easy to clean with a damp cloth or water.
ECM, which is headquartered in Angoulême (in south-western France), develops and manufactures specialist veterinary-science devices. The company also provides training in ultrasound techniques, the correct way to move the probe and how to interpret the ultrasound image.
For more information, please contact:
Simon QuarmbyHOLMEFIELD Farm ServiceAgriculture HouseMurton LaneMurtonYorkT019 5UF
tel : (44) 1904 481.490fax : (44) 1904 481.211email : simon@hfsvets.com
Or visit: http://www.agroscan.com/ and http://www.ecmscan.com/
Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.
Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.
Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."
Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).
According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.
Genitrix has extended its Dentagen dental care range with the addition of Dentagen Aqua, a water additive treatment to control plaque and prevent bad breath in cats and dogs.
Genitrix says the product offers a completely new approach to dental care for companion animals and is expected to prove particularly effective in treating cats which do not respond well to existing treatments, such as dental chews and tooth-brushing.
Dentagen Aqua is a palatable liquid which is added to a pet's drinking water on a daily basis. Its active principal is RF2, a plant extract. According to the company, RF2's ability to enable natural and healthy mouth bacteria to flourish while inhibiting the formation of plaque even at low concentrations has been demonstrated in extensive clinical trials. It operates as an 'anti-biofilm' treatment, modifying the growth of the membrane of oral bacteria to prevent them from producing plaque.
Dentagen Aqua is supplied in a 250 ml bottle costing £6.80. At the recommended dose of 5 ml per day, the bottle will provide 50 days' treatment for a cat or small dog.
In 2008, Genitrix launched the original Dentagen plaque protection system which consists of a unique RF2-impregnated wax provided to practices in a syringe to be applied to the gingival layer and the buccal area of teeth of dogs or cats at end of dental procedures. Dog owners can then maintain the protective coating by giving their pet Dentagen plaque prevention chews. The launch of Dentagen Aqua means that an equivalent solution is now available for cat owners or for dogs which don't eat chews.
With over 85% of dogs and cats over three years old suffering from some form of dental or gum disease, it's the most common health problem in these animals. The market for preventative dental healthcare supplements is estimated to be close to £1 million per annum.
Rob Watkins, Marketing Director at Genitrix, said: "Dentagen exceeded our expectations during its first year and has proved popular with both vets and dog owners. Given the vital importance of good dental health for dogs and cats, it seemed the logical next step to produce a water additive version to make the treatment easier for cat owners in particular."
The Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA) has updated the Vaccination Guidelines it offers to veterinary surgeons.
The association says its Canine and Feline Vaccination Guidelines aim to provide globally applicable recommendations to help veterinary surgeons vaccinate in a standard and scientifically justified fashion.
The VGG has also updated the vaccination guidelines it offers to pet owners and breeders, as well as the series of fact sheets it has created on key global vaccine-preventable diseases of dogs and cats.
The original guidelines were published in 2007 as the WSAVA's initial response to the need for globally applicable recommendations on vaccination best practice. They were updated in 2010 and, since then, the VGG, which is supported exclusively by MSD Animal Health, has been focusing on issues relating to small companion animal infectious disease and veterinary education in Asia.
The 2015 release of the Canine and Feline Vaccination Guidelines is based on a new evidence-based classification system for vaccinology. It also includes a number of additional FAQs (110 in total). The guidelines for both vets and owners/breeders are available for free download at http://www.wsava.org/educational/vaccination-guidelines-group. Currently available in English, they are being translated into a number of languages.
Professor Michael Day, Chair of the VGG (pictured right), said: "The vaccination guidelines are one of the most frequently downloaded resources on the WSAVA's website and are gradually driving a change in vaccination practice throughout the world - a change which is set to have a major impact on day-to-day small animal practice.
"We are delighted to launch these updated versions both for veterinarians and for pet owners and breeders. We hope they will prove even more helpful and ensure that more small animals are vaccinated in a more scientifically-based, robust and safer fashion.
"We would like to thank MSD Animal Health which has been the sole sponsor of the VGG since its inception. Its support enables us to undertake our valuable work."
Ella, a Bloodhound Doberman cross, is the first cold scent dog to work with anti-poaching units in the Eastern Cape of South Africa.
She has been trained specifically to work on crime scenes which are more than a day old and can follow poachers’ tracks to determine their entry and exit points to reserves, as well as their shooting positions.
Medivet says that during her first year, none of the reserves where Ella has been active have lost a single rhino. A number of court cases are also ongoing in other reserves as a result of evidence she has uncovered at crime scenes.
The cost of training Ella, her handler, support vehicle and accommodation has all been funded by the Medivet Rhino programme and by the generous donations of Medivet clients, through the Pennies digital charity box scheme.
To date, Medivet Rhino has raised more than £315,000 via Pennies to help fund this rhino protection programme.
Dr William Fowlds from the Wilderness Foundation Africa (and former Medivet employee) said: "As a cold scent tracking dog, Ella brings a formidable skill set to our anti-poaching units. Her ability to track human footsteps across a variety of terrains, day or night, is a significant deterrent to those thinking of killing our rhinos. In addition, her gentle nature makes her an endearing member of the team so, even though she’s a working dog, we can sneak a little cuddle in every now and again."
He added: "Ella is a game changer in our efforts to protect rhinos. The difference she has made to our work in just one year means that we are now working with our partner, the Chipembere Rhino Foundation, to extend our canine resources. We are indebted to Medivet and its clients for supporting our work by giving us this wonderful dog."
Dr John Smithers, Senior Partner and Project Co-ordinator for Medivet Saving the Rhino, said: "We could not be prouder of Ella’s work to track poachers during her first year in the Eastern Cape of South Africa.
"With her incredible sense of smell, she has brought a new dimension to rhino protection in this region, and all of the agencies involved in protecting this iconic species benefit from her presence.
"We are deeply grateful to all our clients and staff who have supported Medivet Saving the Rhino (through Pennies and other donations) and wish Ella and her support team another successful year ahead."
Virbac Animal Health is launching an initiative to highlight the prevalence of Benign Prostatic Hyperplasia (BPH), a condition suffered by more than 80% of entire male dogs over the age of five1.
The campaign will take place during November - or 'Movember' as it's called by the thousands of men who grow moustaches during the month to raise funds for male prostate and testicular cancer. Virbac says it hopes the campaign will remind dog owners that men are not the only ones to suffer from prostate disorders.
As part of the campaign, the company will be providing participating practices with promotional materials including free dog leads, owner educational and display materials, a press release for local media and practice educational materials.
Chris Geddes MRCVS, Virbac Product Manager, said: "It's estimated that 20% of the country's eight million dogs remain uncastrated throughout their lives. As dogs age, their prostates enlarge, eventually causing symptoms including constipation, lameness and difficulties in urination. However, most of the time clinical signs are absent or vague so diagnosing BPH can be a challenge."
According to Virbac, the traditional rectal examination technique can be an ordeal for both dog and clinician. It's also sometimes inaccurate even in experienced hands and is impossible in very small or large breeds. As a solution, the company has recently introduced Odelis CPSE, the first ELISA test to screen for, diagnose and monitor BPH, available from three UK diagnostic laboratories. The company says it's a cost-effective, precise and reliable alternative to rectal palpation. Virbac also offers Ypozane, a simple tablet treatment for BPH, which takes effect within a week and lasts for six months.
Chris added: "BPH is a serious threat to the health of entire dogs as they get older but owners are often unaware of the potentially serious health problems it can cause if left untreated.
"We hope that, by running our Prostate Awareness Campaign at a time when the media spotlight is already on the dangers of prostate cancer in men, we can help spread the message that owners should also be monitoring older dogs for signs of prostate disease.
"We're providing practices with all the materials they need to promote the campaign in their locality and hope that those getting involved will find it effective in terms of bringing dog-owning clients into the practice for advice on BPH."
For further information on the Prostate Awareness Campaign and to get your free pack please contact your Virbac Territory Manager or contact the company direct on 01359 243243.
Reference1. O'Shea J.D. Studies on the canine prostate gland: Factors influencing its size and weight. J. Comp. Pathol. 1962 72: 321-331.